Association of germline TYK2 variation with lung cancer and non‐Hodgkin lymphoma risk
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34180
Abstract: Deucravacitinib, a novel, selective inhibitor of TYK2 is currently under review at the FDA and EMA for treatment of moderate‐to‐severe plaque psoriasis. It is unclear whether recent safety concerns (ie, elevated rates of lung cancer… read more here.
Keywords: lung cancer; tyk2; lymphoma; risk ... See more keywords
Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Archives of Dermatological Research"
DOI: 10.1007/s00403-018-1858-0
Abstract: Previous studies have reported that genes relating to JAK-STAT pathway (IFIH1, TYK2 and IL-10) conferred the susceptibility to SLE. In this study, we performed a meta-analysis (including 43 studies) to evaluate the association between IFIH1… read more here.
Keywords: ifih1; stat pathway; sle; jak stat ... See more keywords
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Dermatology and Therapy"
DOI: 10.1007/s13555-021-00596-8
Abstract: Deucravacitinib, a novel, oral, selective inhibitor of tyrosine kinase 2 (TYK2) signaling, acts via an allosteric mechanism by binding to the enzyme’s regulatory domain instead of the catalytic domain. This unique binding provides high functional… read more here.
Keywords: jak; kinase; inhibition; tyk2 ... See more keywords
Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
Sign Up to like & getrecommendations! Published in 2024 at "Dermatology and Therapy"
DOI: 10.1007/s13555-024-01262-5
Abstract: Psoriasis, a chronic, immune-mediated, inflammatory disease, affects 2‒3% of the population. Tyrosine kinase 2 (TYK2) mediates cytokine signaling involved in adaptive [interleukin (IL)-12, IL-23] and innate (type-I interferons) immune responses; IL-23–driven T-helper (Th)17 pathways play… read more here.
Keywords: disease; response deucravacitinib; tyk2; expression ... See more keywords
Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.1c01137
Abstract: In this study, we described a series of 2,8-diazaspiro[4.5]decan-1-one derivatives as selective TYK2/JAK1 inhibitors. Systematic exploration of the structure-activity relationship through the introduction of spirocyclic scaffolds based on the reported selective TYK2 inhibitor 14l led… read more here.
Keywords: compound; tyk2; diazaspiro decan; inhibitor ... See more keywords
Catalytically Impaired TYK2 Variants are Protective Against Childhood- and Adult-Onset Systemic Lupus Erythematosus in Mexicans
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-48451-3
Abstract: Type I interferon (IFN-I) pathway plays a central role in the systemic lupus erythematosus (SLE) pathogenesis. Recent data suggest that SLE is associated with variants in IFN-I genes, such as tyrosine kinase 2 (TYK2), which… read more here.
Keywords: adult onset; childhood; systemic lupus; lupus erythematosus ... See more keywords
Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021)
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2022.2026927
Abstract: ABSTRACT Introduction Tyrosine kinase 2 (TYK2) is a member of the JAK family class of kinases that is responsible for mediating the immune response to IL-12, IL-23, and IFNα. The therapeutic value of targeting this… read more here.
Keywords: review; inhibitors potential; selective tyk2; tyk2 ... See more keywords
TYK2 inhibition: changing the treatment landscape for psoriasis?
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2008240
Abstract: Psoriasis is a common immune-mediated inflammatory disease affecting approximately 2% of individuals living in Western countries. Patients with psoriasis suffer from a multitude of comorbidities such as psoriatic arthritis, inflammatory bowel disease, anxiety and depression,… read more here.
Keywords: tyk2; psoriasis; deucravacitinib; poetyk pso ... See more keywords
Tyk2 is a tumor suppressor in colorectal cancer
Sign Up to like & getrecommendations! Published in 2022 at "Oncoimmunology"
DOI: 10.1080/2162402x.2022.2127271
Abstract: ABSTRACT Janus kinase Tyk2 is implicated in cancer immune surveillance, but its role in solid tumors is not well defined. We used Tyk2 knockout mice (Tyk2Δ/Δ) and mice with conditional deletion of Tyk2 in hematopoietic… read more here.
Keywords: tyk2; tyk2 iec; colorectal cancer; tumor ... See more keywords
P133 In vitro pharmacological profile of GLPG3667 suggests differentiation from the TYK2 inhibitors deucravacitinib and TAK-279 at their clinical dose regimens
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0263
Abstract: Tyrosine kinase 2 (TYK2), a Janus kinase (JAK) family member, is attracting a lot of interest as a new target to treat patients with autoimmune and inflammatory diseases, including inflammatory bowel disease, and several inhibitors… read more here.
Keywords: dose regimens; inhibition; tyk2 inhibitors; clinical dose ... See more keywords
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
Sign Up to like & getrecommendations! Published in 2024 at "RMD Open"
DOI: 10.1136/rmdopen-2024-005072
Abstract: In systemic lupus erythematosus (SLE), adaptive immunity is activated by the stimulation of innate immunity, leading to the development of autoreactive T cells and activation and differentiation of B cells. Cytokine signalling plays an essential… read more here.
Keywords: pathology; tyk2; tuning sle; jak tyk2 ... See more keywords